AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Immunology Portfolio by Year
Immunology Portfolio — International operational (constant-currency) growth YoY (%) (%)
AbbVie Immunology Portfolio: 18.8% in FY2025, down 4.3 pts from a year earlier.
Latest, FY2025
18.8%
Period ended Dec 31, 2025
Change on a year earlier
-4.3 pts
23.1% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Immunology | 24,204 | 6,202 | 30,406 | 12.7 | 19.4 | 14.0 | 18.8 | 13.9”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Immunology Portfolio — International operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.8% | -4.3 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 23.1% | +11.3 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 11.8% | +6.1 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 5.7% | -10.5 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 16.2% | -3.0 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 19.2% | +20.0 pts | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -0.8% | -8.2 pts | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 7.4% | – | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
Cite this data
StockData. (2026). AbbVie Immunology Portfolio (%), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-imm-intl-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.